Guobang Pharma605507.SHValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Guobang Pharma (605507.SH) trades at a P/E of 17.50x, P/B of 1.48x, P/S of 1.97x, and a dividend yield of 2.71%.
Longitudinal percentile comparison: P/E sits at the 74th percentile over the trailing 10Y window (vs. 87th percentile over 3Y); P/B sits at the 37th percentile over the trailing 10Y window (vs. 62nd percentile over 3Y); P/S sits at the 32nd percentile over the trailing 10Y window (vs. 54th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 15th percentile within its industry and the 19th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 4.05%, ranking at the 92nd percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 36.8 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 2.71% comes from cash dividends, with an implied ~1.34% from buybacks — a fairly balanced mix of both channels. Guobang Pharma operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHA: 605507 · SSE: 605507 · 605507
Want the full picture on whether Guobang Pharma (605507.SH) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 17.50 | ||||||
| P/B (MRQ) | 1.48 | ||||||
| P/S (TTM) | 1.97 | ||||||
| Dividend Yield | 2.71% | ||||||
| Buyback + Div Yield | 4.05% |